ENSPRYNG

Hoffmann-La Roche Limited🇨🇦 Health Canada

Approval Id: f486007e0a8fccb9
Drug Approval Canada Name: ENSPRYNG
Product Name: ENSPRYNG
Status: Marketed
Status Date: 2020-08-26
Original Market Date: 2020-08-26
Din: 02499681
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Subcutaneous
Schedule: Schedule D , Prescription
Ahfs: 92:20.00
Atc Original: L04AC19 SATRALIZUMAB
Atc Name: l 04 ac 19
Aig Number: 0162294001
Company Name: Hoffmann-La Roche Limited
Company Address: 7070 Mississauga Road, Mississauga, Ontario, Canada, L5N 5M8

SATRALIZUMAB

120 MG / ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

f486007e0a8fccb9

Type

Standard